Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study ; volume:13 ; number:1 ; day:16 ; month:10 ; year:2013 ; pages:1-8 ; date:12.2013
BMC neurology ; 13, Heft 1 (16.10.2013), 1-8, 12.2013
- Creator
-
Balak, Deepak MW
- Contributor
-
Hengstman, Gerald JD
Hajdarbegovic, Enes
van den Brule, Rob JP
Hupperts, Raymond MM
Thio, Hok Bing
SpringerLink (Online service)
- DOI
-
10.1186/1471-2377-13-146
- URN
-
urn:nbn:de:1111-2016030332144
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Balak, Deepak MW
- Hengstman, Gerald JD
- Hajdarbegovic, Enes
- van den Brule, Rob JP
- Hupperts, Raymond MM
- Thio, Hok Bing
- SpringerLink (Online service)
Other Objects (12)
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Disease-modifying treatments in Alzheimer’s disease
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Lithium as a disease-modifying agent for prion diseases
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Disease-modifying treatments in Alzheimer’s disease
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Lithium as a disease-modifying agent for prion diseases
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Disease-modifying treatments in Alzheimer’s disease
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report
Disease-modifying effects of metabolic perturbations in ALS/FTLD